In the span of 24 hours last week, Meta Platforms was found liable by two separate juries in two separate states for two distinct but related categories of harm: child sexual exploitation and the deliberate addiction of adolescents to its platforms. The combined verdicts – $375 million USD in New Mexico on March 24, followed by a landmark addiction liability finding in Los Angeles on March 25 – represent the most consequential legal week in social media history. The -7% weekly drop that followed tells only part of the story: as the chart below shows, Meta had already begun diverging from its Magnificent Seven peers well before the verdicts, and the rulings accelerated a gap that the market had been quietly opening for months.

And yet, on the very same day as the Los Angeles verdict, the White House appointed Mark Zuckerberg to its most influential science and technology advisory council. The juxtaposition is alarming: while the judicial system has finally begun penalizing the company for severe societal harm, the executive branch is actively elevating its leadership to shape national policy.

For years, Big Tech companies have hidden behind Section 230 of the Communications Decency Act and First Amendment protections, claiming they are merely neutral conduits for user-generated content. Last week’s back-to-back rulings pierced that armor: the intentional engineering of infinite scrolling, beauty filters, and hyper-optimized engagement algorithms can now be legally classified as defective and dangerous product design. This marks the precise moment courts begin treating social media platforms as harmful products.

 

Two Verdicts,  Two Theories of Harm. One Week.

The two rulings must be understood together: they address different but compounding aspects of Meta’s impact on children.

On March 24, a New Mexico jury found Meta liable on two counts under state consumer protection law – knowingly engaging in deceptive trade practices, and taking unconscionable advantage of users who did not understand the risks of its platforms. The jury found 75,000 separate violations at $5,000 each, arriving at $375 million USD in civil penalties. The case stemmed from a 2023 undercover operation in which investigators posing as underage users on Facebook and Instagram received sexually explicit material and were solicited by adults – contacts that in several cases led to real-world abuse and human trafficking. It is a deception and facilitation of criminal harm case – a materially more severe legal characterisation than negligence. A second phase in May 2026 will seek additional penalties and court-ordered structural reforms, including mandatory age verification.

The following day in Los Angeles, a jury found Meta (70% at fault) and YouTube (30%) liable for intentionally addicting a young woman to their platforms, causing anxiety, body dysmorphia, and suicidal ideation. Snap and TikTok settled before trial. The dollar amounts – $9 million USD total – are trivial. The significance is systemic: the case is a bellwether for over 1,500 California cases and 2,400+ federal cases consolidated under Multi-District Litigation (MDL), with school district and state Attorney General (AG) trials to follow. The New Mexico AG called his verdict “a historic victory.” The Los Angeles plaintiff’s counsel called theirs “the tip of the spear.”

This Is Not an ESG Controversy – It Is a Product Impact Crisis

ESG ratings measure how a company manages its own sustainability risks – governance, environmental performance, data privacy. Meta scores tolerably on those dimensions, which is precisely why it remains a constituent of iShares, Vanguard, and S&P ESG ETFs. Those screens are doing what they were designed to do. LSEG, for instance, ranks Meta 49th out of 790 tech companies on ESG criteria (94th percentile).

The problem operates on the other axis of the double materiality analysis: how does the company’s activity affect people and the planet? On that dimension, Meta is unambiguous. Two juries found that it knowingly deceived the public about child safety while facilitating criminal predation of minors and deliberately engineering adolescent addiction.

That is not an ESG management failure. It is a product impact crisis – and investors relying on ESG scores alone have been asking the wrong question.

The Evidence Was There

Sustainable Market Strategies has flagged Meta and their product problem in several times over the past eight years. In “Reputation Is Everything” (May 2018), we flagged Facebook’s growing legal exposure following Cambridge Analytica. In “Life in the Shadow of Big Tech” (August 2020), we recommended against the stock, warning that regulatory and advertiser pressure were structural threats to the ad revenue model. In “Thumbs Down: A Socially-Toxic Reputation for Facebook“ (October 2021), we wrote explicitly: “Facebook is increasingly looking like Big Tobacco and/or Big Oil companies – ones which long-refused to recognize the negative impact of their behavior on the environment and society.”

The Tobacco industry spent decades funding friendly science, attacking unfriendly research, lobbying against protective legislation, and settling individual cases quietly to avoid systemic exposure – all while publicly denying causation. Meta has followed every step of that playbook. The difference is that the tobacco industry’s reckoning took 40 years. Meta’s is happening in real time, accelerated by a digital evidence trail its own engineers created.

For seven years, a coalition of institutional investors attempted to force Meta to account for its impact on children through the only mechanism available to them short of litigation – the annual general meeting. Child safety resolutions have been filed at every AGM since 2019. Across multiple votes, independent shareholders supported these proposals at rates consistently between 40% and 63%. None of it mattered. Because Zuckerberg’s Class B shares carry 10 votes each, he routinely controls approximately two-thirds of the total voting power at any AGM, reducing the official support for child safety resolutions to below 20%.

The conduct of the largest passive managers compounded the problem. Vanguard – which holds approximately 9% of Meta’s outstanding shares, making it the company’s second-largest shareholder after Zuckerberg himself – voted in favour of zero out of 400 environmental and social shareholder proposals in both the 2024 and 2025 proxy seasons, including, by definition, Meta’s child safety proposals.

The shift is not confined to courtrooms and academic journals. Among the very users Meta depends on, the perception of harm has crossed a threshold: according to Pew Research, the share of American teenagers who say social media has a “mostly negative” effect on people their age has risen from 32% in 2022 to 48% in 2024 – while those saying it has a “mostly positive” effect has collapsed from 24% to just 11%. Nearly half of all teens now say they spend too much time on these platforms. This is not a fringe view held by regulators or plaintiffs’ attorneys, it is the stated experience of the product’s own users – and it is moving in one direction only.

The Illusion of Federal Oversight: Regulatory Capture in Real-Time

Investors should not expect sweeping federal intervention to mitigate these risks. Meta’s political strategy has been systematic and, until last week, largely invisible to markets.

On the same day the Los Angeles jury delivered its landmark verdict, the White House announced that Zuckerberg had been appointed to the President’s Council of Advisors on Science and Technology (PCAST), alongside Nvidia CEO Jensen Huang, Oracle’s Larry Ellison, Google co-founder Sergey Brin, and Marc Andreessen. This advisory role gives Meta a direct line to shape national technology and tech policy from inside the White House. The appointment echoes the most brazen maneuvers of legacy harmful industries – the modern-day equivalent of the UN appointing a state oil company CEO to preside over a climate summit, or a tobacco lobbyist sitting on a government health promotion board.

The political groundwork runs deeper than a single appointment. Meta gave $1 million USD to Trump’s second inauguration – compared to nothing for the first – and is among the 37 corporate donors to the president’s $300 million White House ballroom project. The KIDS Act, the first federal bill in a decade with a realistic path to protecting children online, has been deliberately stripped of its most consequential provision: the duty of care requirement that would have obliged platforms to design their products with children’s safety in mind.

The Administration that placed a defendant in a child safety trial on its senior science advisory council – on the day of that verdict – is not positioned to regulate that company’s products. The legal accountability for Meta will not come from Washington, but it could come from state attorneys general, state legislatures, and juries and hopefully one day, investors. Litigation risk does not respond to lobbying expenditure the way regulatory risk does, and the battleground is now demonstrably in courtrooms in Albuquerque, Los Angeles, and Frankfort, Kentucky – not on Capitol Hill.

Other jurisdictions are less compromised. Australia enacted a social media ban for under-16 years old in December 2025; the UK is tightening age-verification requirements. Meta has mobilized aggressively against both. The opposition is commercially rational: adolescent engagement is intrinsically necessary to its business model, and the company’s own conduct confirms it.

In 2025, many ESG monikers like “greenwashing” and “net zero” fell by the wayside. However, a fancy term to describe accelerating inequalities has made its way into public discourse: the “K-shaped” economy refers to bifurcated labor, wealth and spending patterns, with the upper arm of the “K” representing wealthy asset owners and high-skilled professionals who are thriving, while the lower arm represents low-to-middle-income earners who are facing stagnant wages and rising costs.

As a result, differentiated spending patterns emerge and creates a stark contrast in prosperity across different groups within the economy.

The bland sobriquet – K-shaped economy – may lull some readers to sleep…but it shouldn’t. It’s just a polite way of saying that U.S. income and wealth inequality is accelerating.

Usually, in a “normal” recovery (V or U-shaped), all boats rise, even if the yachts rise faster than the rowboats. The harsh reality is that U.S. income and wealth inequality is accelerating and bringing it with alarming consequences.

What’s To Blame?

 There are three main factors that we highlight that are driving the divergence in income, wealth and spending:

 
1.
To Own or Not to Own?

The single largest driver of the K is the gap between those who own assets and those who rely solely on labor for income.

 

This is what the hard data tells us, but one can also see it the performance of stock prices.

For example, the media has already made much of the fact that Delta airlines stock have diverged markedly from their peers. This is in large part because the company has focused on higher-tier travel: the majority of their profits are now generated from business and first class tickets. Last year, sales of economy tickets contracted by 7% while premium ticket sales rose by 9%.  

Another example is the banking industry, where there have been clear winners from the “K” – those that cater to high-net worth individuals have seen their stock prices blast off in the past year, while lower tiered banks – those catering to a more diversified clientele – have lagged.

2. The AI Divide

Both the anecdotal and data evidence is making clear that the rapid adoption of Artificial Intelligence is creating a skills gap that serves to reinforces the K-shape.

For example, an analysis of how Anthropic’s chatbot Claude is used by businesses and consumers around the world suggests that richer countries are much more likely to adopt AI. Claude usage per capita remains highly uneven and strongly correlated with GDP, with currently no evidence that low-use countries are catching up.

Equally significant is who is using AI within countries. Research from Anthropic suggests that more educated users are reaping greater productivity benefits from AI because they can give AI chatbots more sophisticated prompts and therefore get better responses. According to Anthropic, “While Claude is able to respond in a highly sophisticated manner, it tends to do so only when users input sophisticated prompts.”

In other words, the rewards from AI are going to higher educated workers who tend to be at the higher end of the income scale (there are exceptions: tech jobs, once considered high-paying and high-demand, are leading the layoffs precisely due to the AI pivot).


3. Asymmetric Impact of Inflation

 U.S. inflation has been running hotter than the Fed’s 2% target for almost half a decade now, but the extra increases in prices don’t hit everyone equally. Essentials like food and housing take up a much larger percentage of low-income budgets and the prices of these items have been rising faster than other consumer prices.

Indeed, households in the bottom 20% of wage earners allocate approximately 63% of their total expenditures to just three categories: housing, food, and transportation. These categories are considered inelastic spending so any price increase in these areas acts as a direct reduction in a family’s standard of living.

 

In contrast, the highest 20% of earners spend roughly 30-35% of their income on these same essentials. When the price of these essential items goes up, wealthier households simply reduce non-essential spending, while for the lower arm of the “K”, that money often comes out of an emergency fund or basic nutrition.

 

How Can Sustainability Investors Navigate the K?

For investors focused on sustainability strategies and outcomes, a K-shaped economy, i.e. the speeding up of income and wealth inequalities, can feel like losing the battle. Indeed, many of the potential winners of inequality are not names one would naturally find on the long side of sustainability themed portfolios (premium banks, private jets, yacht builders, etc.)

Nonetheless, there are many themes that are either orthogonal or even aligned to the realities of a split economy. We highlight three below:

Circular Economy: From an environmental perspective, transforming from a linear to circular economy is widely viewed as necessary because it is considered the only legitimate solution to limiting environmental degradation – the ultimate goal is to decouple resources consumption from economic growth.

From an economic perspective, a decline in purchasing-power for the majority of the population implies more interest and demand for recycling, refurbishing, and “product-as-a-service” (i.e. renting or leasing) models.

Business models based on using less raw inputs, extending the economic life of a product and aiming for substantial improvement in resource performance along the way should be seen as increasingly attractive and a major differentiator. We plan to update our previous work on this subject (Circular Economy: When Going Around in Circles is the Right Thing to Do, April 13, 2022) in the weeks ahead.

Social And Sustainability Bonds: While the interest for green bonds has most likely passed the hype phase of the early 2020s, there appears to be steady interest in other fixed income products tied to sustainability. Social bonds offer a steady yield while directly addressing the “downward” trajectory of the lower-K population.

Earlier this month, the International Finance Corporation (IFC) issued a $2 billion Social Bond The proceeds are specifically earmarked for low-income communities in emerging markets, focusing on healthcare, sanitation, and education. The bond was oversubscribed by an impressive 2.7 times. For investors wanting to make real social impact, financing that is tied to specific project outcomes is a direct way to achieve it.

Sustainable Regenerative Agriculture: With climate-related disasters costing well over 100 billion USD again in 2025, we have argued that climate adaptation (i.e. resilience) will become a necessary investment priority. As we noted above and in previous notes, food prices will continue to outpace generalized inflation due in large part to climate change.

Investing in sustainable farmland and timberland are one of the main ways to combat the impacts of climate change while mitigating risks in our food supply chain (please see, Environmental Assets in Short Supply, October 9, 2025). These assets also provide a hedge against inflation (the lower-K struggle).

Last week at the Consumer Electronics Show (CES) in Las Vegas, “Longevity” effectively replaced “Wellness” as the dominant health theme. The shift was distinct: products moved away from simple fitness tracking (steps and calories) toward clinical-grade biomarkers and biological age. The biggest buzz wasn’t about tracking health KPIs, but measuring how fast you are aging (e.g., Withings’ Body Scan 2 and NuraLogix’s Longevity Mirror).

This narrative was reinforced this week at the J.P. Morgan Healthcare Conference in San Francisco, where Longevity has graduated from a niche side topic to a central pillar of the agenda. The conversation is now framed as “Healthspan” (extending the healthy years of life) and “Metabolic Health.”

For many institutional investors, the narrative has flipped from “Aging Risk” (fewer workers, higher inflation) to the “Longevity Economy” (monetizing the demand for healthspan innovation, senior housing, and retirement income solutions).

The demographic data is staggering: The oldest Baby Boomers (born in 1946) turn 80 years old this year. This is a critical threshold – 80 is the demographic tipping point where healthcare costs triple and the need for assisted living surges. For the first time in history, there are now more people on the planet aged 65 years and older compared with children younger than 5 years.

The result is a “Silver Economy” valued at over $17 trillion. In the current economic environment, a demographic cohort that holds ~70% of disposable wealth and requires specific products – from healthcare to specialized housing – is one of the few guaranteed growth sectors.

In this week’s note, we focus on three promising sub-sectors of the longevity economy. Note that we have previously explored the fourth pillar – Senior Living – in our April 24, 2025 publication The Age of Opportunity: Investments in Eldercare.

 1. Lifestyle, Prevention & Nutrition

For decades, the global healthcare model has operated essentially as “sick care,” intervening only when biological systems fail. The goal is no longer just lifespan, but healthspan, so that vitality lasts as long as the heartbeat.

This shift is creating a massive, recession-resistant market for active prevention. The one billion people over 60 are not looking to spend their accumulated wealth on hospital stays; they are deploying capital into nutrition, functional mobility, and metabolic management to preserve their independence.

Importantly for investors, the winners in this sub-sector are not necessarily the high-risk biotech moonshots, but the established players who already have brand loyalty and can industrialize prevention. These companies are poised to benefit from sticky, recurring revenue streams – once a consumer integrates a metabolic or nutritional protocol, churn is incredibly low because the product transitions from a discretionary choice to a biological necessity.

Companies that have successfully developed a direct-to-consumer relationship are identified below:

 

2. Biopharma, Devices & Medical Innovation

This sector acts as the high-beta growth engine of the longevity theme. We are entering a “Golden Age” of biology where AI is accelerating drug discovery and the narrative has shifted from “curing cancer” to targeting the upstream drivers of aging: metabolic dysfunction, inflammation, and cellular decay.

The investment thesis here is about solving the “hardware” and “software” problems of the human body simultaneously. As the population crosses the 80-year demographic tipping point, demand is pivoting from acute crisis management to systemic maintenance.

We favor companies that provide the essential infrastructure for this shift – whether it’s chemically reprogramming metabolism (such as GLP-1 medication) or physically upgrading the chassis (i.e. surgical interventions) to help keep an aging population both mobile and independent:

 

3. Diagnostics, Monitoring & Digital Health

If biopharma provides the upgrades, the diagnostics sector provides the essential health dashboard. For the vast majority of medical history, healthcare has been flown “blind” – relying on lagging indicators like annual blood draws or the sudden appearance of symptoms. In an aging society, this latency is fatal: treating Stage 4 cancer is exponentially more expensive and less successful than treating Stage 1. Therefore, the economic logic of the longevity economy rests entirely on early detection.

The investment opportunity lies in the technologies that act as the body’s early warning system – detecting metabolic drift, neurodegeneration, and structural decay before they become disasters:

Beyond their alignment with the structural “Silver Economy” megatrend, our selected names demonstrate robust financial health. Unlike speculative biotech plays, these are cash-generative incumbents with defensible moats. This quality is visible in the performance divergence: while the broader S&P Health Care Equipment ETF (XHE) has returned -4.7% over the last three years, the medical equipment and infrastructure leaders in our selection—such as Stryker and Abbott—have delivered strong positive alpha. This reinforces our thesis that in the longevity economy, owning the dominant “maintenance capex” providers offers a superior risk-adjusted return compared to broad index exposure.

If 2025 taught us anything, it is that the impact of Trump’s political orientations on equity prices is often far from what conventional wisdom would predict. In our final note of last year, we highlighted a plethora of sustainability themes that performed far differently than consensus expectations predicted under a Trump government.

Indeed, last year showed investors, including your SMS editors, the need for critical ignoring in order to truly parse the signal from the noise. Though we doubt that Trump will take less space in the news cycle, our 2026 investment outlook is a return to two fundamental questions of investing:

Our relatively sanguine view on equity markets stems from a cool-headed analysis of policy settings. In the U.S., fiscal policy is projected to be modestly positive in 2026 whereas it was restrictive in 2025. There is likely to be Q1 pop in fiscal thrust – thanks to a resumption in federal spending after the shutdown, as well as OBBBA tax cuts that will boost spending (see chart below).

Meanwhile, as the chart below highlights, overall financial conditions have been favourable for some time, and it is hard to see that changing for the foreseeable future; politics at the Fed suggest a dovish configuration for 2026 and beyond.

To be sure, an economic recession in the U.S., occurring in parallel with major weakness in China would put a damper on our moderately bullish thesis. The American labor market is a sore spot – the majority of jobs created over the past year have been in the hospitality and health care sectors, both of which offer under-average wage compensation. But hiring managers still report unfilled positions and continue to be optimistic about hiring; we are resolved to wait until there are definitive signs of a labor market breakdown or unmistakable evidence of a recession before becoming more bearish on risk assets.

Given the above-described policy settings: which sectors offer an attractive risk/reward backdrop to investors in 2026?  Below we highlight six sustainable equity investment ideas that can benefit from mildly favorable policy settings that we believe are primed to outperform.

 

Idea #1: The Grid Super-Cycle: Expansion vs. Integration

Investing in the grid is hardly a contrarian take in 2026. In fact, it is arguably the most crowded trade on the street – but the “why” matters more than the “what.” Most analysis treats the grid as a monolith, indiscriminately buying utilities and equipment makers. We see it differently. The global grid trade has bifurcated into two distinct markets with opposing drivers: the U.S. is in a frantic race for expansion (more capacity for AI), while Europe is fighting for integration (more stability for renewables).

The U.S. “Expansion” Trade:  As we discussed in our October 16, 2025, note “The Energy Transition Just Switched Time Zones”, the U.S, power grid is in aggressive growth mode for the first time in two decades. The driver is no longer just replacing aging poles; it is raw load growth from data centers requiring massive amounts of firm power.

The Rest of World “Integration” Trade:  Outside of the U.S., the narrative flips. Europe isn’t just fighting for more power; it is fighting to stabilize it. As renewable penetration crosses 50%, national grids are breaking under the volatility.

 

Idea #: 2 Dreading Natural Disasters?  Add Long Positions in Dredgers

Despite the political rhetoric, the cost of natural disasters and the need for climate resilience are not going away. Finding climate adaptation plays that go beyond insurance and engineering services companies is sometimes challenging, but one niche segment that deserves more attention from investors is dredging.

Dredging companies are on the front line of combatting rising sea levels and stronger storms that threaten the reliability of ports, flood control channels, and coastal waterways. And beyond climate considerations, dredging is a necessary economic investment. Ports and inland waterways are the backbone of domestic commerce in many countries and in international trade, yet many are not maintained to their necessary depths. Inadequate dredging leads to shipping delays and higher transportation costs. Strengthening supply chains and supporting domestic manufacturing requires well functioning ports and dredging companies are critical.

Two public dredging companies of interest are Great Lakes Dredge & Dock (GLDD), which operates mostly in the U.S., and DEME Group (DEME) that derives most of its revenues in Europe.  

GLDD:  A large share of U.S. dredging revenue is tied to government contracts, which are influenced by appropriations cycles, regulatory approvals, and political priorities.  Fortunately for GLDD, despite Trump having gutted disaster relief agencies like FEMA, funding tailwinds for coastal resiliency and port deepening remain intact -the company has strong backlog visibility (total backlog is over 1.3 times total 2024 annual revenue). Indeed, the company’s value proposition hinges on pairing the industry’s youngest and largest dredging fleet with complex project execution expertise, allowing it to capture market share and higher margins in capital deepening and coastal resiliency work. Importantly, in the U.S., dredging projects are protected from international competition:  the Jones Act requires U.S.-built, U.S.-crewed vessels for domestic dredging, which provides an important moat around the company’s core revenue base:  there are no real U.S. dredging companies that can compete with GLDD.

DEME:  Similar to GLDD, DEME operates in both port and coastal infrastructure dredging, as well as soil and sediment remediation and the company also has significant revenue associated with Engineering, Procurement, Construction, and Installation of offshore wind (foundations, turbine installation, cables) plus oil & gas decommissioning).  The company’s most important moat is its fleet modernization:  DEME operates cutting-edge vessels that allow it to do work in deeper waters and complex installations that legacy fleets cannot match. Investors should note however that DEME is stock is less liquid, given that two major investors own over 70% of outstanding stock.

Over the past year, GLDD stock performance has kept pace with the S&P500, though DEME has lagged. What is more, while the S&P 500 is reaching ever higher valuations (P/E of 29 for the entire market and 23.7 excluding tech), dredging companies have been consistently getting cheaper over the past three years.  Both companies currently trade at 12 times earnings, compared to historical valuations closer to 16 times. With structural tailwinds in place and large project backlogs, both companies offer good value in a critical climate adaptation sector.

 

Idea #3: Short Peabody Coal – The King of a Shrinking Castle

According to the U.S. Energy Information Administration (EIA) and market reports from late 2025, coal consumption by the electric power sector rose by approximately 9% to 11% compared to 2024 in the United States. This was the first year when usage of thermal coal for power generation purposes increased in more than two decades of decline. Stronger power demand coming from data centers and a frigid winter in North America both supported the price of coal pure plays such as Peabody Energy (BTU), which is trading at a five year high.

However, our expectation is that it will be difficult to notch out more coal demand from here. Although it may be true in theory that that the U.S.’ fleet of thermal coal plants has a massive amount of “spare capacity” (roughly half of the fleet sits idle on any given day), most of that capacity is unusable: old  coal plants are hard to restart and are unreliable, and grid capacity near offline plants is insufficient. Overall, we do not expect that the 2025 increase in thermal coal usage is the start of a new trend. In this context, stock investors are currently pricing BTU as if their earnings are far more durable than they are.

Idea #4: Long GLP-1s: The Transition to Essential Medicine

The investment thesis for weight loss drugs is evolving from a consumer discretionary theme to a medical necessity. While 2024 and 2025 were defined by lifestyle adoption, 2026 will likely be driven by clinical indications. Recent data confirms GLP-1 efficacy in treating chronic kidney disease (CKD), heart failure, and addiction disorders. As these drugs secure approval for such indications, insurance reimbursement rates should improve, transitioning the Total Addressable Market (TAM) from a self-pay model to a covered, essential medicine model. Furthermore, the anticipated rollout of oral formulations, led by Novo Nordisk’s oral Wegovy, promises to democratize access by removing the barriers associated with cold-chain storage and injection administration.

A significant investment performance gap emerged in 2025, with Eli Lilly (LLY) appreciating approximately 40% while Novo Nordisk (NVO) corrected by roughly 40%. While Lilly executed well on its pipeline, we believe investors have over-penalized Novo for temporary supply chain constraints. Novo Nordisk remains the global incumbent with the deepest clinical data repository. We view the current valuation disparity as irrational and expect mean reversion in 2026 as Novo resolves supply bottlenecks. For investors seeking diversified exposure to the theme – and protection against single-stock volatility – the Roundhill GLP-1 & Weight Loss ETF (OZEM) offers a balanced basket of approximately 25 companies, capturing both the established duopoly and emerging biotech acquisition targets.

 

Idea #5: Buy a Korean Car – and the Stock

We have outlined in past notes the bullish case for Korea stocks (for example, please see “Seoul Mates: The Case for Korean Sustainability Plays”, May 1, 2025). We especially like Korean EV carmakers.

Korean car makers appear to be much more engaged in electrification compared to their U.S./Japanese counterparts, and the trade deal with the US takes some uncertainty away on the country’s ability to export to the U.S.

To be sure, consensus forecasts for global EV sales in 2026 are not particularly rosy. However, the Korean brands are poised to steal market share from other manufacturers. After all, their build quality is impressive especially given the price. For example, Kia is putting out its K5 EV car at the same price as its ICE sister K4 car. Meanwhile, Hyundai just unveiled it’s robotaxi –a testament to the company’s recent technological catch-up.

We especially like Kia at its current price – the stock is training at very low multiples relative to its peers.

Idea #6: A Word About Oil

Prior to events in Venezuela, short positions in U.S. oil services companies SLB and Halliburton were among our top 2026 investment ideas. The thesis is straightforward: oil services are the part of the supply chain most sensitive to oil prices. With WTI trading at cyclical lows below $60/bbl and a strong consensus for little upside in 2026, drilling activity is likely to remain weak. Historically, after a prolonged period at these prices, oil companies prepare to strand certain fossil fuel assets.

SLB and HAL stock prices traded higher in late 2025 while oil prices traded down—a rare deviation that doesn’t tend to last and often makes for an interesting entry point in short positions.

However, Trump’s intervention in Venezuela and plans for U.S. oil companies to re-enter the country drove a significant pop in U.S. oil companies over the past week. Our editorial team is divided as to whether this price action produces a better opportunity to short or whether to stand aside. Note that oil prices have not rallied since the January 2nd intervention and the world remains well-supplied with heavy crude. The price pop likely reflects optimism that drilling contracts will be awarded to U.S. companies at the expense of other suppliers like Alberta. Trump meets with U.S. oil executives next week to discuss Venezuela; we will wait for more clarity before becoming more bearish on related investments.

Over the last month, political and security turbulence has escalated on multiple fronts. The shooting of conservative commentator Charlie Kirk dominated headlines, amplifying the discourse around political violence. Donald Trump made waves by renaming the Department of Defense to the Department of War. Against this backdrop, Pete Hegseth has convened a special meeting of Department of War leaders this week. Across the Atlantic, a series of Russian drone incursions into allied airspace highlighted the fragility of European security.

In our previous note, “The European Defense Offensive: From Peace Dividend to War Premium”, March 6, 2025, we discussed how guns and drones can help to achieve security and how drones are reshaping entire civilian sectors. The central task for policymakers and investors is to channel these tools toward stability, innovation, and resilience.

 

Back to the Battlefield: The Resurgence of Geopolitics

Since 1980, we experienced a relative period of geopolitical calm, shaped by the end of the Cold War, expanding globalization, and the absence of direct large-scale conflict between major powers. However, this environment has been progressively shifting toward conflicts, with renewed great-power rivalries, regional wars, trade tensions, and escalating competition over resources and technology.

The table below shows the most important conflicts since the beginning of the century. The same conflicts are repeated as they generally remain unresolved as more are added to the list. The projected increases in defense spending for most countries in the world tend to confirm our assessment that tensions are accelerating globally.

The Drone Disruption: From Battlefields to Boardrooms

The Russian invasion of Ukraine has brought the extensive use of drone for reconnaissance and direct attacks into focus and shows how innovation changes the nature of wars. Twenty-five years ago, in Iraq and Afghanistan, insurgents relied on classic guerilla tactics of ambushes and mobility to counter Western military strength. In Ukraine however, drones now serve a similar role. Cheap, nimble, and precise, they harass supply lines and equipment much like guerilla fighters once did.

The chart below shows the exponential rise in demand for drones over the past five years as well as the  continued exponential growth expected to occur in future years. As described above, military use is growing due to larger defense budgets and the transformation of armed forces towards more drone usage. In the civilian sector there are increasing commercial and societal uses.

From an investment perspective, the combination of military and non-military uses is appealing since it amounts to a certain diversification in demand; military spending does not tend to follow the economic cycle, whereas drone demand from non-military sources tends to more cyclical.

Indeed, for sustainable investors, drones are increasingly being deployed in ways that deliver tangible benefits for society:

Importantly, this civilian transformation of drone technology echoes a broader historical pattern: many advances that originated in military research such as GPS, the internet, and satellite imaging eventually delivered immense benefits for public use. In the same way, drones are now transitioning from instruments of conflict to powerful tools for society where demand is growing.

 

The Gun Market’s Surprising Stall

Surprisingly even with greater polarization, gun demand in the U.S. has plateaued following the post-COVID surge. Several forces explain this: many households already own multiple guns, crisis fatigue has diminished the urgency to arm, and inflation has constrained discretionary spending.

The chart below shows two indicators highlighting the COVID peak in gun demand and the recent plateauing in the United States; the largest market in the world. Background checks from the National Instant Criminal Background Check System (NCIS) are a good leading indicator of new gun demand in the United States whereas firearms manufacturing from the Annual Firearms Manufacturing and Export Report (AFMER) is a coincident to lagging indicator because manufacturers respond to current demand.

Despite persistently high homicide rates in the U.S., the political landscape leaves little room for meaningful gun legislation, and this affects the firearms market. Paradoxically, in the past, fears of tighter regulation have triggered surges in gun sales, i.e. people purchase guns in anticipation of not being able to in the future. However, with a Supreme Court broadly supportive of expansive Second Amendment rights, the likelihood of new restrictions is low, which removes the urgency to purchase additional firearms.

The map below shows that the U.S., Mexico and Brazil have among the highest firearms homicide rates and yet stronger gun control legislation is unlikely in the near future. In the United States, the current administration does not favor stricter rules. In Mexico, civilian ownership is tightly regulated but illicit firearms traficking is a powerful source of demand. In Brazil, Bolsanaro loosened gun laws when he was president while Lula has issued executive orders to tighten gun control because the Brazilian Congress is ambivalent to enact stronger regulation.

The Promise of Drones (Go Long) vs. the Limits of Guns (Be Short)

Unlike drones, which have evolved from military origins to offer wide-ranging civilian and environmental benefits, guns and munitions lack such positive spillover potential for society. Firearms are designed with a single purpose: to wound or kill, and their civilian proliferation is more often linked to rising homicide rates, accidents, and social costs rather than broad social gains.

The table below shows drone and drone-adjacent companies that offer societal benefits and positive financial attributes and gun companies to avoid from a sustainable investment standpoint.

The chart below shows market capitalization, sustainability scores, growth in sales and price to sales for companies in our targeted long and short sectors There are not yet many large companies considered to be specializing in drones; the larger companies like Nokia, Honeywell and Leonardo manufacture components used in drones as part of their much larger organization. The same can be said for gun manufacturers as they remain small capitalization. As expected from our sectoral analysis above, drone companies are experiencing strong growth: for example, Red Cat has had exceptional growth in the last five years (78% growth in sales), it is also expected to continue as its price-to-sales of 128 highlights. On the other hand, gun companies have had close to zero growth in sales and trade at depressed price-to-sales. We expect this trend to continue: high valuation in the growth segment of drones and low valuation in the stagnating gun segment.

Nine months into Trump’s presidency, its contours are taking shape. Beyond campaign promises—tax cuts, manufacturing revival, and drilling expansion – the U.S. government has taken a strong tack toward interventionism. From interference at the Fed to taking stakes in American companies, Trump’s republicanism is vastly different from preceding Presidents of the same party.

Indeed, Trump’s growing intervention, especially in corporate affairs, is fueling concerns that the U.S. is shifting away from the so-called laissez-faire economy. That said, with equity markets at new highs and both government and corporate bond yields trading in a relatively tight range, one might be hard pressed to find evidence that it matters, yet!

In 2021, we published a note ( “Macro Goes ESG” July 8, 2021) that outlined our high conviction view that fiscal and industrial policy would become dominant policy levers in the coming decade. Although we were far too optimistic that interventionist governments would address voter preferences such as climate change and socioeconomic inequalities, our forecast of government interventionist policies is proving true.  

Important for investors is that unlike monetary policy which “lifts (sinks) all boats”, fiscal and industrial policy creates winners and losers. This is true for sustainability themes and financial markets at large.

In today’s Macro Meets Sustainability quarterly update, we discuss the three main U.S. government interventions that have evolved since Trump took office.

  1. Mar-A-Lago and USD: Beware the Kindleberger Trap

The Kindleberger Trap – named for economic historian Charles Kindleberger – posits that global stability depends on a leading power that is willing and able to supply public goods that benefit the international community. When the dominant power fails to fulfill this role, the international system becomes prone to conflict and economic crisis.

For investors, the essential public good that keeps the global economy out of the Kindleberger trap is the U.S. dollar acting as the world’s reserve currency. Reserve currencies are necessary in global trading systems to facilitate international transactions and act as a store of value, and they tend to impose two characteristics on the reserve status country:

The so-called Mar-a-Lago Accord is an attempt in our view to have one’s cake (low interest rates, access to capital) and eat it too (revive the domestic industrial and manufacturing sector) but does not consider the consequences of falling into a “Kindleberger trap”.   If the U.S. is unable or unwilling to maintain policy that ensures the greenback as the world’s reserve currency, it is unlikely that foreign nations and investors will risk asset value erosion by currency devaluation or inflation (see the section below).

To this end, there is more evidence that investors are becoming nervous about the impacts of U.S. policy on the greenback: equity investors are aggressively increasing currency hedges. According to a recent FT article and Deutsche Bank data, over 80% of the 7 billion USD that has flowed into foreign domiciled U.S. ETFs in the past three months has been on a hedged basis, compared to 20% at the beginning of the year. In other words, investors still want to own U.S. equities but are wary of the currency.

The bottom line is the current U.S. administration’s desire to decrease the trade deficit risks obliterating a key public good – a stable reserve currency – and sending the global economy into a Kindleberger trap, with the concomitant increase in volatility in financial markets. We believe that currency hedging is fully justified for non-U.S. investors exposed to U.S. markets and/or the currency risk should create a significant home bias in sustainable investments.

2. Monetary Interference: Stoking Inflation

Recent events and nominations at the Fed underscore President Trump’s intention to politicize the central bank and the outcome of last week’s FOMC meeting gave a good indication of how investors should think about policy stimulus in the current regime. Recall that last week, the FOMC voted to lower interest rates while simultaneously upgrading the economic outlook and increasing its expectation for inflation over the next year (to a level well above 2%). Thus, we believe that investors should position for both lower central bank rates and higher inflation, as it marks an important deviation from the conventional central bank’s playbook. Since 1982 (when Volcker broke the back of runaway inflation), monetary policy generally fell into four quadrants:  

  1. Interest rates are becoming stimulative (rates are below the neutral rate and falling while the economy is weakening and lower inflation is anticipated)
  2. Interest rates are becoming less stimulative (rates are below the neutral rate and rising while economic growth is bottoming and higher inflation is anticipated).
  3. Interest rates are becoming increasingly restrictive (rates are above the neutral rate and rising because the economy is running hot and higher inflation is anticipated).
  4. Interest rates are becoming less restrictive (rates are above the neutral rate and falling as economic growth is peaking and lower inflation is anticipated).

By signaling that rates can go lower while economic and inflation accelerates, it is becoming more probable that the Fed will de-emphasize its objective on inflation stability and focus on maximum employment and low interest rates.  

Historically, low rate and higher inflation environments have favored real estate plays and other real assets. For ideas that fit squarely within a sustainability framework, please see our recent notes on this subject: It’s About to Get Real, August 21, 2025 and The Age of Opportunity: Investments in Eldercare April 23, 2025.

  1. Corporate Interventionism: From Invisible Hand to Tightening Grip

In 2024, the IMF published a new data set that documents emergent patterns of policy intervention associated with the return of industrial policy. In one year, they recorded over 2,500 new industrial policies worldwide, of which 71% are considered trade distorting. This is perhaps not surprising to anyone watching the news flow. In the past quarter alone, the following U.S. developments have occurred:

These are perhaps the most jaw-dropping developments, not least of all because they occurred at the firm-specific level, which represents almost half of all the interventions documented by the IMF (see table below).

The IMF’s database also categorizes policy interventions by their motivating factor. Interestingly, supply chains and climate change – considerations that both fit squarely within sustainability investing – feature prominently (see the chart below). The one caveat is that the data was collected from 2009 to 2023 and researchers noted that in the most recent year, measures focused increasingly on national security, and less on competitiveness.

The rise of industrial policy and interventionist governments is far from a uniquely U.S. phenomenon (see the table below). A case in point is this month’s announcement from Canada’s Prime Minister Mark Carney, which unveiled the first phase of the country’s “nation building” projects, all five of which could be classified by the IMF as being motivated by climate change or supply chains and include energy production (nuclear), energy transport (LNG), mineral production (copper, gold) and supply chains (port expansion).

An investment backdrop that is dominated by political catalysts implies an environment where active portfolio management is necessary because sectoral, thematic, and geographic winners and losers will be produced. Critically, this applies equally to sustainability themes. While ESG has become a touchy subject and there is no longer a wholesale buying of related equity products, companies that derive revenue from specific sustainability themes (e.g. waste management, green infrastructure, carbon) have had excellent performance so far during Trump’s reign.  

Sustainability winners and losers are likely to run along thematic lines that are heavily influenced by both perceived threats and actual policy pivots; carbon is an excellent example, as discussed in last week’s note (Contrarians in the Green,  September 18, 2025).

Last February, our note on the food industry argued that the likelihood of ongoing food inflation coincided with the signing of President Trump’s Executive Order (EO) “Establishing the President’s Make America Healthy Again Commission”. We made the case that RFK Jr.’s pledge to take on Big Food – along with several other factors – is a potential source of inflation since it would surely increase the cost of food production (Food Fight: Policy’s Effect on Food Producers & Inflation, February 13, 2025).

The February 13th Executive Order required the MAHA commission to submit a “Make Our Children Healthy Again” strategy but the draft that was submitted earlier this month is so vague that – for now – we are removing MAHA from our list of potential food inflation pressures. Unless there are major changes to the official version (to be released in the coming weeks), the MAHA strategy is all hat and no cattle – it lacks ambition regarding two critical sustainability topics: pesticide overuse and processed food consumption.

The Ultimate “Influencer”: Big Ag

The MAHA “hope” was that RFK would implement policy to reduce pesticide use in U.S. farming practices. After all, the U.S. is second largest consumer of pesticides and continues to increase pesticide use per unit of land at a faster pace than elsewhere (see chart below).

In addition to the volume of pesticide use, the U.S. is also an outlier in terms of the types of pesticides used. According to the most recent information collected, there are over 85 pesticides that have been banned in the European Union, China or Brazil that are still permitted in the U.S. today.

The primary MAHA attack related to pesticides is glyphosate (i.e. Roundup), originally made by Monsanto, which is now owned by Bayer, the German chemical and pharmaceutical giant. MAHA (and many others) purport that glyphosate is cancer-causing. The problem is that for each study that concludes that it is, there is another (often industry-backed) that concludes that it isn’t. This has led the EPA to say that “there are no risks of concern to human health when glyphosate is used in accordance with its current label”.

A small number of giant corporations have amassed monopoly or near-monopoly power over this and other pieces of the food and agriculture system in the (see chart below) and these companies prefer the status quo.

Indeed, it didn’t take long to round up the lobbyists to push back against MAGA when it comes to pesticides: The National Corn Growers Association, The American Soybean Association, The National Association of Wheat Growers, and the International Fresh Produce Association all implored President Trump to walk back the claims made in the February MAHA Commission report and it seems that they have been a major influence.

It’s no wonder that the industry pushed back on MAHA; pesticide manufacturers had their fair share of struggles over the past several years. The chart below shows the three-year performance of the largest pesticide companies. Only Corteva, whose sales are split between both seeds and pesticides has kept pace with the broad equity benchmark.  

Even more profound than MAHA threats, oversupply and aggressive price competition from China have cut deeply into both topline growth and margins of the major producers. Note that U.S. import tariffs from China will include pesticides should the 90-day pause fail to be extended.  With about half of all sales derived in the U.S., Corteva would likely continue to be the relative winner should a more protective trade backdrop develop. Note that this is not an endorsement for the company since Corteva is hardly a sustainability leader; the company ranks particularly poorly in environmental and social scores according to CSRHub and has its fair share of controversies.

Ultraprocessed Seems Ultrasafe From MAHA

The draft MAHA strategy doesn’t have much taste when it comes to Big Food either. The MAHA “hope” was that government finds ways to reduce access to unhealthy food choices. After all, on average, 55% of calories consumed by Americans come from ultra-processed foods (for youth aged 1–18 years this number is a staggering 62%!).

Last February, we explored how investors should position within the food sector should MAHA policy become a catalyst for change in the food production industry. We noted that it was a relatively straightforward exercise to find potential short candidates based on the share of sales derived from the sweets and snack foods category (Pepsi Co., Mondelez, Hershey, Nestle, Barry Callebaut and Kellanova (the latter is the snack division spun off from Kellogg’s). Half of these companies have had negative returns since the start of the year (Barry Callebaut, Kellanova, and PepsiCo) while only two have matched or exceeded the performance of the broad market (Hershey’s and Nestle).

We also noted that finding “sustainability winners” is significantly more difficult in this segment since, even once we remove the companies with the greatest revenues derived from junk food, what is left is hardly a recipe for good health. What’s more, the food majors are fraught with controversy risk; the table below shows just how rampant greenwashing is within this industry.

The MAHA draft contained little substance on how food quality could be improved or even how these companies should communicate about their products. RFK’s pet concerns (food dyes, infant formula) are addressed, but the report largely states that the major systemic problems need more “research”.

The bottom line is that we are downgrading the threat that MAHA will have much of an impact on food companies’ equity performance. Investors are most likely to turn their focus back to other drivers of returns in this sector: ingredient costs, availability of labor, and appetite suppression related to GLP-1 medication:

 

In sum, both the MAHA threat and other bearish factors are less acute today than six months ago. Included in our top short investment ideas of 2025 (“2025 Investment Playbook: Going Green In A Brave New World” January 9, 2025) were short positions in Mondelez (+3%), PepsiCo (-3%). While the sustainability case against these snack companies remains fervent, the catalysts for a more profound bear market have receded for now.  

Real assets are uniquely positioned to thrive in a higher inflation environment because they derive revenue from long-term contracts or have built-in inflation pass-through mechanisms. Whether it’s regulated utilities with tariff escalators, toll roads indexed to inflation, or real estate entities adjusting rents upward, their cash flows tend to preserve purchasing. Moreover, these assets often own tangible, hard infrastructure that can reprice in line with rising input costs, providing both income stability and inflation protection for investors. On top, they have underperformed over the last five years.

Demand for real assets is poised to strengthen as investors seek stable, long-term cash flows with pricing power against a backdrop of chronic undersupply, following decades of underinvestment in real assets outside of China. Real assets align with sustainable investors’ goal by being involved in the energy transition, urban development and digitalization.

 

Moving away from 2% inflation

During the 2010s, inflation in advanced economies consistently undershot central banks’ 2% targets. Structural factors such as globalization, geopolitical stability and subdued wage growth kept price pressures muted. This led to accommodative monetary policy and historically low interest rates as policymakers were concerned about disinflation and the risk of inflation remaining too low. As the chart below shows, since 2020, the backdrop has shifted dramatically. A combination of pandemic-related supply disruptions leading to expansive fiscal stimulus and the reversal of structural factors such as demographics, de-globalization and geopolitical instability have pushed inflation well above 2%.

Moreover, the recent firing of the Bureau of Labor Statistics (BLS) commissioner following a weaker-than-expected payroll report underscores the risks of politicizing economic data and undermines the perceived neutrality of the U.S.’s economic reporting agency. Inflation is one area where the temptation to tamper with the data is greatest: social security outlays are often tied to inflation and central banks target inflation. Nudging official inflation numbers lower would reduce the cost of social security and could lower interest rates to decrease the interest cost of the debt.

Recent actions by President Trump leads us to believe that coercive actions to let the inflation target drift higher than 2% by keeping interests rate lower are likely to take place in the United States while the outlook for inflation seems tilted to the upside.

 

Outlook for Inflation: Upward Pressure

The table below highlights the drivers most likely to influence inflation in the future. The majority of these are likely to push inflation higher over the next five years unless artificial intelligence (AI) provides enough productivity gains to offset a shrinking labor force, re-industrialization, tariffs and growing geopolitical tensions.

Higher inflation combined with political pressure to keep interest rates low could propel a real assets recovery.

What are real assets?

At their core, real assets are tied to physical, tangible infrastructures that provide essential services. Because of their underlying economic function, they tend to offer stable and predictable cash flows, often supported by regulated pricing frameworks or long-term contracts. This income stability allows many real asset companies to maintain attractive dividend yields, making them appealing to investors seeking current income alongside potential capital appreciation. Because of the relative predictability of their cash flows, they generally carry more debt than most companies.

Another defining feature of real assets is their sensitivity to macroeconomic conditions, particularly inflation and interest rates. The long-duration nature of their cash flows means valuations can be pressured when rates rise, but the essential nature of their services often provides inflation pass-through mechanisms. This makes them valuable as a hedge against inflation, while their tangible asset base offers downside protection in periods of market stress. Furthermore, many of these assets align closely with long-term themes such as decarbonization, elder care and digitalization, often giving them defensive qualities and exposure to secular growth drivers and sustainability themes.

 

Sustainable Real Assets

The table below highlights how real assets are represented throughout economic sectors and how they can contribute sustainably to society.

A Sample Portfolio of the Best Aligned Companies

We single out one company in each economic segment that has the best combination of sustainability scores (using CSRHub) and alignment to sustainability according to our proprietary SMS Sustainability Alignment percentage that reflects revenue assigned to sustainability themes. As we can see from the graphic below, the companies have much better scores and alignment than the median market company.

Is the rough patch behind us?

 Below are performance charts for the stock price for each real asset segment compared to a World equity Index since 2020. Very few of the companies have been able to outperform the market Index. The main reason is that interest rates were rising during the period (in response to higher inflation).  Since 2023, the overall market has recovered but, for real assets, the negative effects of higher interest rates continue to be felt.

Looking specifically at each segment, starting with the sustainable environmental infrastructure companies selected, performance has been positive albeit has lagged the world index. The company Waste Management is the exception, benefitting from exceptional operational efficiency, organic growth and a good acquisition strategy.

Transportation has been having difficulties since 2022.

Social infrastructure has generally done better, especially Ensign which is providing post-acute care. It has expanded rapidly while delivering from an operational basis to a population getting older.

For natural capital and digital infrastructure, Weyerhaeuser, SBA Communications and Digital Realty have lagged the market.

Finally, to round out to 20 companies, we added a group of diversified names that operate across a few segments of real assets. Increasing interest rates have been especially difficult for them but they have been recovering lately.

Why invest now

As articulated above, the path of least resistance is  higher inflation that will not be fought too hard by central banks. This should benefit companies with pricing power insulated from inflation that can tolerate a relatively high debt load.

Below is a table comparing an equal-weight portfolio of the sustainable companies we identified with a global index. The portfolio delivers greater dividends, has a lower return on equity and a higher debt load than the broad market. In other words, inflation with a weak central bank response should be  a good recipe for this portfolio.

There’s a famous line in Bruce Springsteen’s Atlantic City: “Down here it’s just winners and losers, and don’t get caught on the wrong side of that line.” Today, it seems that line is drawn between those whose productivity will be augmented by AI and those who will be displaced by it.

This note examines how the AI revolution will reshape the labor market. We explore how once-enviable service-sector jobs will be affected and how Artificial General Intelligence (AGI) — if ever achieved — will likely amplify income and wealth inequalities over the coming decades. We begin with the macro view — who benefits from AI-driven productivity gains — and then drill down to industry-level effects.

Will AI Benefit Workers or Profits?

Historically, disruptive technologies have had unequal impacts depending on skill levels, income brackets, gender, and sector. Many consider AI the most significant General-Purpose Technology (GPT) since the internet in the late 1990s.

From a macro perspective, if AI can “lift all boats” by driving higher productivity, it is crucial to understand whether those gains will flow to corporate profits (and shareholders) or to workers. To answer this, we must examine how past technological breakthroughs affected worker productivity and the subsequent growth in real wages as technology integrated into daily workflows.

If productivity growth tends to translate into higher real wages over the long run, then AI’s impact on worker productivity — particularly in the services sector, which accounts for roughly 80% of GDP in many advanced economies — should, in theory, benefit those whose work is augmented by AI.

However, while labor productivity and real wage growth tracked closely until the mid-1970s, the relationship began breaking down in the 1980s as globalization expanded the labor pool and wage pressure increased. In recent decades, faster technological change — and its positive effects on productivity — has been less profitable for workers, with gains flowing largely to corporate profits.

Corporate profits as a share of national income are now at record highs, while wage share has continued to decline. Unless taxation or redistribution mechanisms change, most AI-driven gains will likely keep flowing to shareholders rather than workers.

Displaced, Augmented, or Dropped?

Every technological shift forces workers to adapt — but not all can or will. Encouragingly, a recent McKinsey & Co. survey found that many employers expect AI to create a net increase in jobs in most functions, except for service operations, supply chain management, HR, and manufacturing. While this is positive news overall, it underscores the need for workers in certain functions to adapt quickly.

Similarly, PwC’s Fearless Future: 2025 AI Jobs Barometer shows that jobs with “some exposure” to AI are still growing, but at a slower rate than jobs in occupations where AI is less relevant or not applicable.

Unlike past disruptions — such as the offshoring-driven manufacturing job losses of the early 2000s — the workers most at risk today are in coveted service-sector roles, many requiring advanced education. One striking example: the author recently saw a man in downtown Toronto wearing a sandwich board reading “Junior programmer looking for work” — a scenario almost unimaginable just two years ago. Such rapid shifts could spark political and social unrest, as displaced, highly educated workers may influence policy debates much as displaced “Rust Belt” manufacturing workers did during the 2016 U.S. election. A recent article even suggests that Silicon Valley may have mishandled the junior IT job market

A recent OECD study suggests that jobs most affected by AI are disproportionately held by highly educated white men in their prime working years — a politically influential demographic in many developed economies. Some researchers argue that this “overproduction” of educated elites could fuel additional instability.

The takeaway: not all well-educated workers will be augmented by AI to the same degree, and many will drop out of the labor market entirely, unable to integrate AI into their workflows. This is especially pronounced in services, where senior roles may benefit most from productivity gains while junior roles face displacement. As a result, workers in the top income quartiles are likely to see faster wage growth than those in lower quartiles.

Research by Apollo suggests that the two highest income quintiles — already accounting for roughly 60% of total spending — will further increase their share of consumption in the coming years.

This trend is already visible. Since 2018, earners in the top income quartiles have increased real consumption by 15%, five percentage points more than the lower quartile.

There has hardly been a week in 2025 without major developments rocking the pharmaceutical sector. The industry was spared in the first wave of U.S. tariffs but is bracing for significant disruption.

A striking signal of this is the sharp rise in U.S. pharmaceutical imports during Q1 2025, as companies rushed to stockpile drugs ahead of potential trade barriers (see chart below). In March alone, imports jumped 160% year-over-year.

This week’s note builds on our March 13 analysis (“Investing in U.S. Healthcare: The Big and Small of It”), with a focus on the pharmaceutical sector. We concentrate on three key developments:

Together, these measures reflect a strategic shift: reducing foreign reliance and curbing drug costs in the name of national security—while simultaneously delivering on tax-cut promises (which heightens pressure on federal healthcare spending). With so many moving parts—and a great deal of speculation— navigating related equity markets is increasingly complex. This note aims to identify which pharmaceutical segments and companies are most exposed to these policy pressures, and where investors may find resilience.

Why Make Health a Matter of National Security?

Healthcare spending in the U.S. is huge—reaching 16.7% of GDP in 2023, far above the 11% average among peer countries. Yet this spending hasn’t translated into better overall outcomes: Americans still face significantly higher mortality rates across major health issues, as the data below makes clear.

This disconnect becomes even more stark when considering that the U.S. makes up less than 5% of the global population but accounts for over half of total pharmaceutical sales.

Americans pay, on average, nearly three times more on prescription drugs than residents of other OECD countries, and over four times more for branded medications. This is partly due to limited price negotiation power for public insurers and longer patent protections, which delay the arrival of cheaper generics.

Framing affordability as a matter of sovereignty, the Trump administration has argued that foreign governments “extort” lower drug prices, shifting the cost burden onto Americans. Despite an executive order signed to “equalize” global drug pricing, the launch of the Section 232 national security investigation examining pharmaceutical imports could result in tariffs and ultimately push U.S. prices higher.

This higher spending is no doubt burdensome for American citizens, but it is not without benefits for the country. U.S. pharma wields immense influence: FDA approval is prioritized globally, and around 30% of drugs approved in the U.S. remain unavailable in Europe two years later.

Nonetheless, lowering drug prices has become a rare point of bipartisan agreement. Biden’s Inflation Reduction Act (IRA) initiated historic negotiations on insulin and high-cost Medicare drugs. However, Trump proposed changes that would weaken the Medicare Drug Price Negotiation Program—for instance, by delaying the inclusion of small molecule drugs by 4 additional years, which would exempt many high-cost medications from negotiation.

First, let’s turn to trade—where drug supply chains are being reframed not just as economic assets, but as strategic vulnerabilities.

Rewiring Pharma Supply Chains

The Section 232 investigation launched by the U.S. government seeks to determine whether dependence on foreign pharmaceutical imports poses a national security threat. The outcome of the investigation could be deemed a justification for tariffs, to encourage domestic production. While the formal conclusion of the investigation could take up to nine months, the imposition of tariffs may occur much sooner—potentially within weeks, according to the U.S. commerce secretary.

Trump has mentioned a 25% tariff rate on pharmaceutical imports. Countries most vulnerable to this policy shift are in Europe and Asia (particularly China and India) due to their dominant roles in the supply of active pharmaceutical ingredients to the U.S.

These regions have also developed specializations that make them essential in today’s healthcare landscape:

Tariffs would hit generic drugs hardest—a segment that makes up 90% of U.S. prescriptions by volume. Most generics are produced abroad, especially in India. With already slim margins, a 25% duty could render some products economically unviable.

Tariffs are also particularly concerning for essential injectables like chemotherapy drugs, already prone to shortages. ING estimates a 24-week cancer drug supply could become $10,000 more expensive under proposed tariffs. The head of the Association for Accessible Medicines warns some drugs may disappear from the U.S. market entirely.

The table below highlights pharmaceutical segments and regions most exposed to tariff risk, while also identifying companies with supply chains more insulated from high-risk geographies. Our analysis focused on the 20 largest companies by market cap in each segment, along with names already included in our investment universe. Those identified under the “less vulnerable” column have been vetted for strong scores across material operational performance metrics.

The concentration of production abroad—especially for low-margin, high-need drugs—makes tariffs a blunt tool with uncertain outcomes. Critics of Trump policies argue that instead of penalizing imports, the U.S. should offer incentives for reshoring—or work to stabilize prices through multilateral frameworks. Without this, tariffs could weaken supply chains, reduce access and ultimately further inflate prices—the very issues the policy aims to fix.

Trump’s Drug Pricing Plan: A Push for Affordability… or Popularity?

Trump’s push to lower U.S. drug prices re-emerged with an executive order signed on May 12. It calls for “most-favored-nation” pricing—benchmarking U.S. drug costs to those in the lowest-cost peer countries—and proposes direct-to-patient sales from manufacturers.

While the order touts price cuts of up to 90%, its potential impact remains limited. Similar efforts under Trump’s first term were blocked in court, and the new order lacks legal weight, a timeline, or defined drug categories. As experts put it, “executive orders are wish lists”.

Still, the strategy marks a shift—leveraging U.S. market power not just to lower domestic prices, but also to pressure foreign governments to raise theirs. EU pharmaceutical executives, seeing increased competitiveness and challenges, have echoed calls for price hikes in Europe to sustain innovation and avoid trade retaliation.

Though the Trump administration has expressed intent to reframe Medicare’s drug price negotiation program, any meaningful pricing relief would still depend on targeting the most used, highest-cost medications covered by federal programs. We therefore reiterate the views expressed in our March 13th note (“Investing in U.S. Healthcare”), which identifies the large pharmaceutical companies and specific drugs most at risk, along with smaller companies worth considering.

The feasibility of achieving large-scale price drops remains difficult due to legal and institutional hurdles—namely, constitutional challenges to price caps and the administrative complexity of implementing negotiated pricing.

That said, the administration has demonstrated its willingness to act elsewhere—most notably through broad-based federal program spending cuts.

 Federal Cuts Will Loosen the Safety Net

The “Big, Beautiful Bill” passed by the U.S. House in late May introduces sweeping fiscal changes that, among other things, could drastically reshape the nation’s federal healthcare programs. The legislation proposes nearly $700 billion in Medicaid cuts over a decade, potentially leaving over 10 million people without coverage. Work requirements—80 hours monthly of work, school, or service—would apply broadly for the first time in Medicaid’s 60-year history. Past state-level trials to implement work requirements led to coverage losses without boosting employment, as most recipients are actually already employed or unable to work (as exposed below).

Beyond cutting off millions of people from needed healthcare coverage, the policy threatens companies dependent on these programs. Those most at risks are discussed below.

For pharmaceutical manufacturers, we identify those whose revenues are significantly tied to Medicaid programs based on the Centers for Medicare & Medicaid Services data. The following table lists publicly traded companies with the highest exposure to Medicaid, by revenue contribution.

Exposure to public reimbursement has long been seen as defensive—but in this case, it’s where the sharpest cuts may land. Note that many of the companies we flagged in the section above as being relatively unaffected by tariffs are nonetheless highly vulnerable to Medicaid cuts, underscoring that pharma companies are suffering from multiple policy cross-currents.